Other substances

Sb23

A synthetic anti-RBD (of SARS-CoV-2 spike protein) nanobody.

Phase of research

Potential treatment - pre-clinical evidence

How it helps

Antiviral

Drug status

Experimental

1
 Supporting references
0
 Contradictory references
0
 AI-suggested references
0
 Clinical trials

General information

Sb23 is a synthetic nanobody (a single-domain antibody) identified for SARS-CoV-2 spike protein RBD affinity via library screening using ribosome display and phage display rounds of selection (Custódio et al., 2020).

 

Supporting references

Link Tested on Impact factor Notes Publication date
Selection, biophysical and structural analysis of synthetic nanobodies that effectively neutralize SARS-CoV-2
Biophysical assay In vitro Antibody 		in vitro biophysical assay; cryo-EM; HEK293T-ACE2 cells 12.12

The synthetic nanobody strongly binds to the SARS-CoV-2 spike protein RBD at the site of its interface with host ACE2 (an outcompetes it in vitro). The nanobody (especially when fused with an Fc domain) neutralizes SARS-CoV-2 spike pseudotyped virus (IC50 down to 7 ng/ml for Sb23-Fc).

 Nov/04/2020
Export (.csv)